Wire · opportunities
FDA OKs Immunotherapy After Surgery for Stage 3 dMMR Colon Cancer
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 9 October 2026 · Fusion42 review
The FDA has approved the use of atezolizumab immunotherapy after surgery and chemotherapy for patients with stage 3 dMMR colon cancer, reducing the risk of cancer recurrence or death by 50%. This marks a new standard of treatment for this specific colon cancer subtype.
This Wire brief sits within Fusion42's coverage of Biotech, and 5 sources have reported it between 8 Oct 2026 and 10 Oct 2026.
◆ ◆ The Wire takeaway
You now face a market where post-surgical chemo for dMMR colon cancer must compete with immunotherapy that halves recurrence risk. This opens a direct sales path if you build immuno-oncology tools or patient management support in colorectal cancer.
◆ Coverage
5 sources · first reported 8 Oct 2026 · latest 10 Oct 2026
◆ Related on Wire
◆ Topics